Literature DB >> 3332516

Immunotherapy of infectious diseases: past, present and future.

J E Pennington1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3332516      PMCID: PMC2376418     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


× No keyword cloud information.
  10 in total

1.  Intravenous administration of human gamma-globulin.

Authors:  S BARANDUN; P KISTLER; F JEUNET; H ISLIKER
Journal:  Vox Sang       Date:  1962       Impact factor: 2.144

2.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. I. THE CHARACTERIZATION OF THE PROTEIN FRACTIONS OF HUMAN PLASMA.

Authors:  E J Cohn; J L Oncley; L E Strong; W L Hughes; S H Armstrong
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

3.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; G J Small; M E Lostrom; G B Pier
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

4.  Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host.

Authors:  J E Pennington; G J Small
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

5.  Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice.

Authors:  R J Kurlander; J Hall
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

Review 6.  Group G streptococcal infections.

Authors:  P N Gaunt; D V Seal
Journal:  J Infect       Date:  1987-07       Impact factor: 6.072

7.  Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.

Authors:  M S Collins; R E Roby
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

8.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Authors:  S L Morrison; M J Johnson; L A Herzenberg; V T Oi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

9.  Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli.

Authors:  A S Cross; W Zollinger; R Mandrell; P Gemski; J Sadoff
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

10.  THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : II. THE COURSE OF THE INFECTIOUS PROCESS.

Authors:  K Goodner; D K Miller
Journal:  J Exp Med       Date:  1935-08-31       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.